Shougang Guo

Shougang Guo

Auto-generated profile, based on publicly available information

Shougang Guo

Department of Neurology, Shandong Provincial Hospital Affiliated to Shandong First Medical University

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2018 in Journal of the Neurological Sciences
Verified
Journal Article
Closed access
YYYang Yang
Yang Yang
CWChun-Juan Wang
Chun-Juan Wang
BWBao-Jie Wang
Bao-Jie Wang
ZZZi-Ling Zeng
Zi-Ling Zeng
SGShou-Gang Guo
Shou-Gang Guo

1 June 2017 in Journal of the Neurological Sciences
Verified
Journal Article
Closed access
BWBao-Jie Wang
Bao-Jie Wang
CWChun-Juan Wang
Chun-Juan Wang
ZZZi-Ling Zeng
Zi-Ling Zeng
YYYang Yang
Yang Yang
SGShou-Gang Guo
Shou-Gang Guo

2 June 2022 in Frontiers in Immunology
Verified
Journal Article
Open access
BWBaojie Wang
Baojie Wang
CWChunjuan Wang
Chunjuan Wang
JFJianli Feng
Jianli Feng
MHMaolin Hao
Maolin Hao
SGShougang Guo
Shougang Guo
Objective: This study aimed to determine the clinical characteristics and evaluate the efficacy of immunotherapy and the long-term prognosis of severe autoimmune encephalitis (AE) in China.Methods: Clinical features, laboratory or radiological findings, and treatment outcomes of 60 severe patients with AE from January 1, 2014, to December 31, 2020, were collected. Continuous variables were compared using the t-test and the nonparametric Mann–Whitney U test, as appropriate. Univariate and multivariable logistic regression analyses were performed to assess the correlations between factors, treatment responses, and prognosis of severe AE.Results: The median age of symptom onset was 35 years. Tumors were identified in 23.3% of patients, and 36/60 (60%) patients responded to first-line immunotherapy. Second-line immunotherapy was implemented in 26/60 (43.3%) patients. A significant clinical benefit was observed in 19/26 (73.1%) patients treated with lower dosage rituximab; seven patients were still refractory and received bortezomib as an add-on therapy. During the last follow-up, 48/60 (80%) patients achieved good outcomes (mRS, 0–2), and 10 died. Seventeen patients experienced relapses. A high CD19+ B-cell count (OR, 1.197; 95% CI [1.043–1.496]; p = 0.041) and a lower neutrophil-to-lymphocyte ratio (NLR; OR, 0.686; 95% CI [0.472–0.884]; p = 0.015) predict the response to first-line treatment and good prognosis, respectively.Conclusions: Patients with severe AE were in critical condition at baseline but could be salvaged after effective rescue immunotherapy. A lower dosage of rituximab could be an optimal option for severe AE. CD19+ B-cell count and NLR may provide prognostic information for predicting treatment response and outcome of severe AE.

1 January 2019 in Journal of Clinical Neurology
Verified
Journal Article
Open access
XZXiaoting Zhang
Xiaoting Zhang
CWChunjuan Wang
Chunjuan Wang
WZWenyao Zhu
Wenyao Zhu
BWBaojie Wang
Baojie Wang
HLHuiying Liang
Huiying Liang
SGShougang Guo
Shougang Guo
Anti-N-methyl-D-aspartate receptor (anti-NMDAR) encephalitis is the most common type of autoimmune encephalitis. This study aimed to explore the possible factors affecting the response to first-line treatments in patients with anti-NMDAR encephalitis. We enrolled 29 patients who were diagnosed as anti-NMDAR encephalitis between January 1, 2015, and June 30, 2018. They were divided into the remission and nonremission groups according to their response to first-line treatments. The demographics, clinical manifestations, main ancillary examinations, follow-up treatments, and prognosis of patients were recorded. The symptoms reported on in this study occurred before treatments or during the course of first-line treatments. There were 18 patients (62.07%) in the remission group and 11 patients (37.93%) in the nonremission group. Compared to the remission group, a higher proportion of the patients in the nonremission group exhibited involuntary movements, decreased consciousness, central hypoventilation, lung infection, and hypoalbuminemia. The nonremission group had a high incidence of increased intracranial pressure and significant elevations of the neutrophil-to-lymphocyte ratio in peripheral blood (NLR), aspartate aminotransferase, and fibrinogen. Six patients (54.55%) in the nonremission group received second-line immunotherapy. Only one patient (3.45%) died, which was due to multiple-organ failure. Anti-NMDAR-encephalitis patients with more symptoms-especially involuntary movements, disturbance of consciousness, central hypoventilation, and accompanying hypoalbuminemia and pulmonary infection-may respond poorly to first-line treatments. Positive second-line immunotherapy therefore needs to be considered. Admission to an intensive-care unit, increased cerebrospinal fluid pressure, and increased NLR might be the significant factors affecting the response to first-line treatments.

22 November 2023 in Journal of Biological Chemistry
Verified
Journal Article
Open access
DQDanqing Qin
Danqing Qin
CWChunjuan Wang
Chunjuan Wang
DLDong Li
Dong Li
SGShougang Guo
Shougang Guo
Oligodendrocyte precursor cells are present in the adult central nervous system, and their impaired ability to differentiate into myelinating oligodendrocytes can lead to demyelination in patients with multiple sclerosis, accompanied by neurological deficits and cognitive impairment. Exosomes, small vesicles released by cells, are known to facilitate intercellular communication by carrying bioactive molecules. In this study, we utilized exosomes derived from human umbilical cord mesenchymal stem cells (HUMSCs-Exos). We performed sequencing and bioinformatics analysis of exosome-treated cells to demonstrate that HUMSCs-Exos can stimulate myelin gene expression in oigodendrocyte precursor cells. Functional investigations revealed that HUMSCs-Exos activate the Pi3k/Akt pathway and regulate the Tbr1/Wnt signaling molecules through the transfer of miR-23a-3p, promoting oligodendrocytes differentiation and enhancing the expression of myelin-related proteins. In an experimental autoimmune encephalomyelitis model, treatment with HUMSCs-Exos significantly improved neurological function and facilitated remyelination. This study provides cellular and molecular insights into the use of cell-free exosome therapy for central nervous system demyelination associated with multiple sclerosis, demonstrating its great potential for treating demyelinating and neurodegenerative diseases.

1 May 2021 in Journal of Neuroimmunology
Verified
Journal Article
Closed access
TWTingting Wang
Tingting Wang
BWBaojie Wang
Baojie Wang
ZZZiling Zeng
Ziling Zeng
HLHonghao Li
Honghao Li
FZFusheng Zhang
Fusheng Zhang
SGShougang Guo
Shougang Guo